文献速递膀胱癌与上尿路尿路上皮癌

高级别上尿路尿路上皮癌中PD-1与PD-L1表达的预后价值

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2017-06-28

基于国际上尿路尿路上皮癌协作组423例接受切除性手术的高级别上尿路尿路上皮癌患者组织芯片,PD-1阳性者占37.2%、PD-L1阳性者占26.2%。多因素分析显示PD-1阳性是癌症特异性生存(HR 1.7,95%CI 1.03-2.66,p=0.039)和总生存(HR 1.5,95%CI 1.05-2.24,p=0.029)的独立预后因素;在器官局限性疾病中PD-L1阳性是复发无生存(HR 0.2,95%CI 0.06-0.98,p=0.046)和总生存(HR 0.3,95%CI 0.11-0.63,p=0.003)的独立预后因素。

要点

  • 肿瘤浸润淋巴细胞PD-1阳性与不良病理特征相关,且是癌症特异性生存和总生存的独立预后因素。
  • 肿瘤细胞PD-L1阳性在器官局限性疾病(pT2或更低、pN0/x、cM0)中是复发无生存和总生存的独立预后因素。
  • PD-1阳性者占37.2%、PD-L1阳性者占26.2%,中位随访37.0个月。

核心结论

  • 肿瘤浸润淋巴细胞PD-1阳性与不良病理标准相关,且是更差生存结局的独立预后因素。
  • 肿瘤细胞PD-L1阳性在器官局限性疾病中是良好生存结局的独立预后因素。

研究设计与样本

  • 来自国际上尿路尿路上皮癌协作组的423例接受切除性手术的高级别上尿路尿路上皮癌患者组织芯片。
  • 采用免疫组化染色PD-1和PD-L1,抗体包括Cell Marque™ NAT105(稀释1:250)和预稀释E1L3N®。
  • 肿瘤浸润淋巴细胞(PD-1)和肿瘤细胞(PD-L1)染色率≥1%定义为阳性。
  • 进行单因素和多因素分析评估生存结局的独立预后因素。

主要发现

  • 患者中位年龄70.0岁,中位随访37.0个月。
  • PD-1和PD-L1阳性率分别为37.2%和26.2%。
  • PD-1阳性与不良病理特征显著相关,而PD-L1阳性与有利的pT分期相关。
  • 单因素分析中PD-1表达与更差的复发无生存、癌症特异性生存和总生存相关。
  • 多因素分析中PD-1表达是癌症特异性生存(HR 1.7,95%CI 1.03-2.66,p=0.039)和总生存(HR 1.5,95%CI 1.05-2.24,p=0.029)的独立预后因素,但不是复发无生存(HR 1.4,95%CI 0.9-2.16,p=0.139)的独立预后因素;单因素分析中PD-L1表达与生存结局无显著相关;在器官局限性疾病(pT2或更低、pN0/x、cM0)患者的多因素分析中,PD-L1阳性是复发无生存(HR 0.2,95%CI 0.06-0.98,p=0.046)和总生存(HR 0.3,95%CI 0.11-0.63,p=0.003)的独立预后因素。

关键数值与推荐

  • PD-1阳性定义为肿瘤浸润淋巴细胞染色率≥1%。
  • PD-L1阳性定义为肿瘤细胞染色率≥1%。
  • PD-1阳性率37.2%,PD-L1阳性率26.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. MATERIALS AND METHODS: Tissue microarrays of 423 patients treated with extirpative surgery for high grade upper tract urothelial carcinoma from the International Upper Tract Urothelial Carcinoma collaboration were stained for PD-1 and PD-L1 using antibodies, including Cell Marque™ NAT105 diluted 1:250 and prediluted E1L3N® via immunohistochemistry. A 1% or greater staining rate of tumor infiltrating lymphocytes (PD-1) and tumor cells (PD-L1) was considered positive. Univariate and multivariate analyses were performed to assess independent prognosticators of survival outcomes. RESULTS: Median patient age was 70.0 years and median followup was 37.0 months. PD-1 and PD-L1 were positive in 37.2% and 26.2% of patients, respectively. PD-1 positivity was significantly associated with adverse pathological characteristics while PD-L1 positivity was associated with favorable pT stage. On univariate analysis PD-1 expression was associated with worse recurrence-free, cancer specific and overall survival. On multivariate analysis PD-1 expression was an independent prognosticator of cancer specific survival (HR 1.7, 95% CI 1.03-2.66, p = 0.039) and overall survival (HR 1.5, 95% CI 1.05-2.24, p = 0.029) but not recurrence-free survival (HR 1.4, 95% CI 0.9-2.16, p = 0.139). On univariate analysis PD-L1 expression was not significantly associated with survival outcomes. However, on multivariate analysis in patients with organ confined disease (pT2 or less, pN0/x and cM0), PD-L1 positivity was an independent prognosticator of recurrence-free survival (HR 0.2, 95% CI 0.06-0.98, p = 0.046) and overall survival (HR 0.3, 95% CI 0.11-0.63, p = 0.003). CONCLUSIONS: PD-1 positivity of tumor-infiltrating lymphocytes was associated with adverse pathological criteria and independent prognostication of worse survival outcomes. PD-L1 positivity of tumor cells was an independent prognosticator of favorable survival outcomes in cases of organ confined disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Krabbe LM, Heitplatz B, Preuss S, et al. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017. PMID: 28668287. doi:10.1016/j.juro.2017.06.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。